Coherent receives ISO 13485 certification for Goettingen facility

Article

Coherent Inc. has recently expanded its ISO 13485 certification in Europe to include the Excimer laser design and manufacturing facility located in Goettingen, Germany.

Santa Clara, Calif., Sept. 11, 2009 — Coherent Inc. (Santa Clara, CA) (Nasdaq: COHR) has recently expanded its ISO 13485 certification in Europe to include the Excimer laser design and manufacturing facility located in Goettingen, Germany. ISO 13485 is an international standard that defines the requirements of comprehensive quality management systems for the design, development, production, customer service and assembly of medical devices. ISO 13485 also specifies protocols for adherence to customer requirements and product improvement within the European regulatory framework for medical devices.

“Achieving ISO 13485 certification benefits all customers who integrate Coherent’s excimer laser products into their surgical systems for eye correction,” notes Heiner Felder, Quality Manager for Medical Products. “The Goettingen certification provides Coherent’s medical customer with expanded capabilities and supplements the existing ISO 13485 certification of the Munich facility. We have now successfully integrated and synchronized all our quality systems for excimer lasers within Coherent.”

Founded in 1966, Coherent, Inc. is a Russell 2000 Index company and a world leader in providing laser-based solutions to the commercial and scientific research markets. Please direct any questions to Heiner Felder, Quality Manager for Medical Products at +49 89 5892746 10. For more information about Coherent, including product and financial updates, visit our website at:
www.coherent.com/excimer

Contact details
Petra Wallenta, PR Manager Europe
+49 89 5892746 25
petra.wallenta@coherent.com

Heiner Felder
+49 89 5892746 10
heiner.felder@coherent.com

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.